A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis

Bibliography

• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 2009;113(13):2895-901
   PubMed Web of Science ®Google Scholar
• Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma 2013;54(2):242-51
   PubMed Web of Science ®Google Scholar
• Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2014;20(1):89-97
   PubMedGoogle Scholar
• Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89(12):1233-7
   PubMed Web of Science ®Google Scholar
• Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97(10):1570-3s
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d’Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009;146(2):223-5
   PubMedGoogle Scholar
• Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007;110(9):2012-18
   PubMed Web of Science ®Google Scholar
• Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;116(3):576-81
   PubMedGoogle Scholar
• Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009;113(22):5394-400
   PubMed Web of Science ®Google Scholar
• Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the mayo clinic. Cancer 2006;107(2):361-70
   PubMed Web of Science ®Google Scholar
• Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103(2):505-11
   PubMed Web of Science ®Google Scholar
• Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol 2011;86(1):96-8
   PubMedGoogle Scholar
• Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: eastern cooperative oncology group (ECOG) phase 2 trial E4903. Blood 2010;116(22):4436-8
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129(6):771-5
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10(2):127-40
   PubMed Web of Science ®Google Scholar
• Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112(6):2190-8
   PubMed Web of Science ®Google Scholar
• Poulsen A, William A, Blanchard S, et al. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). J Comput Aided Mol Des 2012;26(4):437-50
   PubMed Web of Science ®Google Scholar
• Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95(1):19-29
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006;6(8):671-9
   PubMedGoogle Scholar
• Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111(3):1686-9
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352(17):1779-90
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365(9464):1054-61
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363(12):1117-27
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2014;99(2):292-8
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25(11):1751-9
   PubMed Web of Science ®Google Scholar
• Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116(24):5089-102
   PubMed Web of Science ®Google Scholar
• Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004;103(5):1901-8
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J 2011;1(11):e44
   PubMedGoogle Scholar
• Novotny-Diermayr V, Hart S, Goh KC, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2012;2(5):e69
   PubMedGoogle Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198(6):851-62
   PubMed Web of Science ®Google Scholar
• Martini M, Hohaus S, Petrucci G, et al. Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. Am J Clin Pathol 2008;129(3):472-7
   PubMed Web of Science ®Google Scholar
• Melzner I, Weniger MA, Bucur AJ, et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006;118(8):1941-4
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30(33):4161-7
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Odenike O, Scott B, et al. Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis. ASH Annual Meeting Abstracts 20 November 2009; 2009. 3905
   Google Scholar
• Deeg HJ, Odenike O, Scott BL, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. American Society of Clinical Oncology Annual Meeting 2011
   Google Scholar
• Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts 18 November 2011; 2011. 282
   Google Scholar
• Cell Therapeutics. Oral pacritinib versus best available therapy to treat myelofibrosis. In: NLoM. Bethesda, MD: 2013; Clinical Trial Number NCT01773187
   Google Scholar
• Cell Therapeutics. Oral pacritinib versus best available therapy to treat myelofibrosis with thrombocytopenia. In: NLoM. Bethesda, MD: 2014; Clinical Trial Identifier Number: NCT02055781
   Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27(6):1322-7
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115(6):1131-6
   PubMed Web of Science ®Google Scholar
• Carroll J. Updated: in another big cancer setback, Sanofi shutters fedratinib program. FierceBiotech: FierceMarkets. 2013
   Google Scholar
• Verstovsek S, Tam CS, Wadleigh M, et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res 2014;38(3):316-22
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29(7):789-96
   PubMed Web of Science ®Google Scholar